Luspatercept

BATCH NUMBER: To be announced

1.257,00 €

Minimum order quantity: 2

Therapeutic Luspatercept antibody from the original Reblozyl® commercial drug

Drug Aliquots On Demand

  • Commercial drug sourced in the EU
  • Delivery within 2-4 weeks​
  • Buffer: original drug buffer​
  • Quantity: minimum order quantity required​
Need support? Please contact us

Product specifications:​

  • Product Concentration 50 mg/mL
  • Volume per vial 40 µL
  • Quantity per vial 2 mg
  • Batch Number to be announced
  • Storage Temperature 2-8 °C / -80 °C
Our products are for research use only. The “therapeutic expiration date” implies expiry date for patient adminstration and is not applicable to the shelf life of the aliquot. Aliquot storage at -86°C ensures fully functional molecules even after the mentioned expiry date

Product Information:

Evidentic offers repackaged finished pharmaceutical products (e.g RMP/RLD). We refer to the repackaged RMP/RLD products synonymously as drug aliquots or aRMP, or short: aliquots.

We offer batches of original drug aliquots in low-binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

As ‘raw material’ for the production of drug aliquots, Evidentic sources RMP from the European (EU) market. As a licensed pharmaceutical wholesaler, Evidentic is committed to Good Distribution Practice (GDP) compliance with respect to the procurement, storage and shipment of RMP.
Drug aliquots are manufactured by repackaging RMP in a qualified laboratory. The aliquotation process is performed under a quality and manufacturing agreement between Evidentic and the contract manufacturer. Repackaging of RMP includes the following steps: opening the secondary and primary RMP containers and transferring the specified volumes of RMP into an Eppendorf 0.5 ml low-binding (or similar) tube. If the RMP is a lyophilized powder and not a highly concentrated solution, reconstitute the RMP according to the original manufacturer’s instructions and then aliquot as a highly concentrated solution.
For identification purposes, drug aliquots are labeled with the date of aliquoting, the original lot number of the RMP, the original expiration date of the RMP, the name of the active ingredient (INN), and a unique identification code.
Immediately after aliquoting, drug aliquots are stored at either 2-8 °C or -86 °C for long-term storage. All drug aliquots stored at 2-8 °C are transferred to -86 °C at least two weeks before the expiration date of the original RLD/RMP is reached. Further quality or functional testing are not performed on the drug aliquots.  

Target

Class of molecule

Isotype

Host cells

Chinese Hamster Ovary (CHO) cellscells

Prepared from

Reblozyl ®

Therapeutic Area

Therapeutic Indications

Mechanism of Action (MoA)

Luspatercept, an erythroid maturation agent, is a recombinant fusion protein that binds selectedtransforming growth factor-β (TGF-β) superfamily ligands. By binding to specific endogenous ligands (e.g. GDF-11, activin B) luspatercept inhibits Smad2/3 signalling, resulting in erythroid maturation through differentiation of late-stage erythroid precursors (normoblasts) in the bone marrow.

Pharmacotherapeutic group​​

Antianaemic preparations

List of Excipients​

Citric acid monohydrate (E330)
Sodium citrate (E331)
Polysorbate 80
Sucrose
Hydrochloric acid (for pH adjustment)
Sodium hydroxide (for pH adjustment)

Not looking for Luspatercept?

Search our therapeutic molecules product database

Evidentic GmbH
Martin-Buber-Str. 10
14163 Berlin

+49 (0) 30 959 99 8831 info@evidentic.com
Linkedin Youtube Facebook Twitter
Open Cookie Preferences
Evidentic Support
+49 (0) 30 959 99 8831

Let us know about your inquiry details and we’ll contact you shortly.